VRNA vs. KNSA, PCRX, SYRE, LGND, IRWD, PIRS, DCPH, COLL, GMTX, and ABCL
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Kiniksa Pharmaceuticals (KNSA), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Pieris Pharmaceuticals (PIRS), Deciphera Pharmaceuticals (DCPH), Collegium Pharmaceutical (COLL), Gemini Therapeutics (GMTX), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Verona Pharma (NASDAQ:VRNA) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Comparatively, 54.2% of Kiniksa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Kiniksa Pharmaceuticals has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kiniksa Pharmaceuticals had 23 more articles in the media than Verona Pharma. MarketBeat recorded 26 mentions for Kiniksa Pharmaceuticals and 3 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.78 beat Kiniksa Pharmaceuticals' score of 0.32 indicating that Verona Pharma is being referred to more favorably in the media.
Verona Pharma received 146 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 79.90% of users gave Verona Pharma an outperform vote while only 64.06% of users gave Kiniksa Pharmaceuticals an outperform vote.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Verona Pharma's net margin of 0.00%. Kiniksa Pharmaceuticals' return on equity of -7.32% beat Verona Pharma's return on equity.
Verona Pharma presently has a consensus price target of $33.60, indicating a potential upside of 119.46%. Kiniksa Pharmaceuticals has a consensus price target of $30.00, indicating a potential upside of 70.36%. Given Verona Pharma's higher probable upside, equities analysts plainly believe Verona Pharma is more favorable than Kiniksa Pharmaceuticals.
Verona Pharma has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
Summary
Kiniksa Pharmaceuticals beats Verona Pharma on 9 of the 17 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
